Status:
UNKNOWN
Clinical Impact of Dedicated MR Staging of Ovarian Cancer
Lead Sponsor:
The Netherlands Cancer Institute
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The only chance of cure for patients with advanced stage ovarian cancer is complete cytoreductive surgery (CRS). The only way to determine whether complete CRS can be achieved is by a laparoscopy. How...
Eligibility Criteria
Inclusion
- Patients with advanced stage (FIGO stage III or IV) ovarian cancer scheduled for primary or interval cytoreductive surgery
- Age \>18 years
- Written and signed informed consent
- WHO 0-2
- Able to read and write Dutch
Exclusion
- Patients with contraindications for MRI
- Patients with contraindications for CRS
- Known additional malignancy
Key Trial Info
Start Date :
April 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT03399344
Start Date
April 13 2018
End Date
July 1 2022
Last Update
May 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NKI-AVL
Amsterdam, Netherlands, 1066CX